US BioTec Inc
US BioTec, Inc. engages in the development, manufacture, marketing, and distribution of bio-degradable, nontoxic, and noncarcinogenic products in the United States. Its product portfolio consists of approximately 30 products, which stimulate plants that produce crops; correct microbial and mineral problems present in soils; and rehabilitate the soil ecosystem by breaking down the residual build-u… Read more
US BioTec Inc (USBC) - Total Assets
Latest total assets as of March 2005: $939.54K USD
Based on the latest financial reports, US BioTec Inc (USBC) holds total assets worth $939.54K USD as of March 2005.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
US BioTec Inc - Total Assets Trend (2003–2005)
This chart illustrates how US BioTec Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
US BioTec Inc - Asset Composition Analysis
Current Asset Composition (December 2005)
US BioTec Inc's total assets of $939.54K consist of 54.9% current assets and 45.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 5.5% |
| Accounts Receivable | $286.29K | 32.0% |
| Inventory | $155.75K | 17.4% |
| Property, Plant & Equipment | $310.57K | 34.8% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2003–2005)
This chart illustrates how US BioTec Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: US BioTec Inc's current assets represent 54.9% of total assets in 2005, a decrease from 94.6% in 2003.
- Cash Position: Cash and equivalents constituted 5.5% of total assets in 2005, the same as 5.5% in 2003.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2003.
- Asset Diversification: The largest asset category is property, plant & equipment at 34.8% of total assets.
US BioTec Inc Competitors by Total Assets
Key competitors of US BioTec Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Nanjing Red Sun Co Ltd
SHE:000525
|
China | CN¥6.84 Billion |
|
ADAMA Ltd
SHE:000553
|
China | CN¥49.93 Billion |
|
Grand Industrial Holding Co Ltd
SHE:000626
|
China | CN¥8.43 Billion |
|
Qinghai Salt Lake Industry Co.Ltd
SHE:000792
|
China | CN¥50.97 Billion |
|
Sichuan Meifeng Chemical Industry Co Ltd
SHE:000731
|
China | CN¥5.17 Billion |
|
Asia Potash International Investment Guangzhou Co Ltd
SHE:000893
|
China | CN¥19.38 Billion |
|
Hubei Xinyangfeng Fertilizer Co Ltd
SHE:000902
|
China | CN¥19.75 Billion |
|
Sichuan Lutianhua Co Ltd
SHE:000912
|
China | CN¥9.46 Billion |
US BioTec Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - US BioTec Inc generates 1.83x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - US BioTec Inc is currently not profitable relative to its asset base.
US BioTec Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.46 | - | - |
| Quick Ratio | 1.14 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | $267.88K | - | - |
US BioTec Inc - Advanced Valuation Insights
This section examines the relationship between US BioTec Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 6.4% |
| Total Assets | $893.81K |
| Market Capitalization | $0.96 USD |
Valuation Analysis
Below Book Valuation: The market values US BioTec Inc's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: US BioTec Inc's assets grew by 6.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for US BioTec Inc (2003–2005)
The table below shows the annual total assets of US BioTec Inc from 2003 to 2005.
| Year | Total Assets | Change |
|---|---|---|
| 2005-12-31 | $893.81K | +6.45% |
| 2004-12-31 | $839.68K | +15.34% |
| 2003-12-31 | $728.01K | -- |